This session will assess treatment options for patients with aspirin-exacerbated respiratory disease in light of the most recent data available on both aspirin therapy and new biologic therapy for asthma and nasal polyps.
LEARNING OBJECTIVES:
Upon completion of this activity, participants should be able to:
- Apply the latest data on biologics in asthma and nasal polyps to the patient population with AERD Identify patients with AERD who should be considered for aspirin desensitization
- Define the benefits and risks of aspirin and biologic therapy for patients with AERD